IRVINE, Calif., Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.
Bernard Zovighian, chief executive officer, and Scott B. Ullem, chief financial officer, are scheduled to speak to conference attendees at 11:00 a.m. ET. A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at http://ir.edwards.com/. An archived version of the webcast will be available later that day on the Edwards investor relations website.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
| Last Trade: | US$74.31 |
| Daily Change: | -0.48 -0.64 |
| Daily Volume: | 612,077 |
| Market Cap: | US$43.830B |
May 01, 2025 April 23, 2025 April 18, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
